Personalized prostate cancer screening: Improving PSA tests with genomic information

Science Translational Medicine

Volumn 2, Issue 62, 2010, Pages

  Witte, John S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA MICROSEMINOPROTEIN; FIBROBLAST GROWTH FACTOR RECEPTOR 2; HEPATOCYTE NUCLEAR FACTOR 1BETA; KALLIKREIN; KALLIKREIN 3; PROSTATE SPECIFIC ANTIGEN; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR TBX3; UNCLASSIFIED DRUG; BETA-MICROSEMINOPROTEIN; FGFR2 PROTEIN, HUMAN; KALLIKREIN RELATED PEPTIDASE 3, HUMAN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; PROSTATIC SECRETORY PROTEIN; T BOX TRANSCRIPTION FACTOR; TBX3 PROTEIN, HUMAN; TELOMERASE; TERT PROTEIN, HUMAN; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER SCREENING; CANCER STAGING; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC VARIABILITY; GENOMICS; HUMAN; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT INDICATION; BLOOD; EARLY DIAGNOSIS; GENETICS; MALE; METHODOLOGY; NOTE; PROSTATE TUMOR;

EARLY DETECTION OF CANCER; GENETIC MARKERS; HUMANS; KALLIKREINS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROSTATIC SECRETORY PROTEINS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; T-BOX DOMAIN PROTEINS; TELOMERASE; TUMOR MARKERS, BIOLOGICAL;

EID: 78650504559     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3001861     Document Type: Review

References (29)

1. M. J. Hayat, N. Howlader, M. E. Reichman, B. K. Edwards, Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 12, 20-37 (2007).
2. M. J. Barry, Screening for prostate cancer - The controversy that refuses to die. N. Engl. J. Med. 360, 1351-1354 (2009).
3. K. L. Greene, P. C. Albertsen, R. J. Babaian, H. B. Carter, P. H. Gann, M. Han, D. A. Kuban, A. O. Sartor, J. L. Stanford, A. Zietman, P. Carroll, Prostate specific antigen best practice statement: 2009 update. J. Urol. 182, 2232-2241 (2009).
4. A. Vickers, A. Cronin, M. Roobol, C. Savage, M. Peltola, K. Pettersson, P. T. Scardino, F. Schröder, H. Lilja, Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: An independent replication. J. Clin. Oncol. 28, 2493-2498 (2010).
5. J. Gudmundsson, S. Besenbacher, P. Sulem, D. F. Gudbjartsson, I. Olafsson, S. Arinbjarnarson, B. A. Agnarsson, K. R. Benediktsdottir, H. J. Isaksson, J. P. Kostic, S. A. Gudjonsson, S. N. Stacey, A. Gylfason, A. Sigurdsson, H. Holm, U. S. Bjornsdottir, G. I. Eyjolfsson, S. Navarrete, F. Fuertes, M. D. Garcia-Prats, E. Polo, I. A. Checherita, M. Jinga, P. Badea, K. K. Aben, J. A. Schalken, I. M. van Oort, F. C. Sweep, B. T. Helfand, M. Davis, J. L. Donovan, F. C. Hamdy, K. Kristjansson, J. R. Gulcher, G. Masson, A. Kong, W. J. Catalona, J. I. Mayordomo, G. Geirsson, G. V. Einarsson, R. B. Barkardottir, E. Jonsson, V. Jinga, D. Mates, L. A. Kiemeney, D. E. Neal, U. Thorsteinsdottir, T. Rafnar, K. Stefansson, Genetic correction of PSA values using sequence variants associated with PSA levels. Sci. Transl. Med. 2, 62ra92 (2010).
6. S. A. Strope, G. L. Andriole, Prostate cancer screening: Current status and future perspectives. Nat. Rev. Urol. 7, 487-493 (2010).
7. R. M. Hoffman, S. B. Zeliadt, The cautionary tale of PSA testing. Arch. Intern. Med. 170, 1262-1263 (2010).
8. F. H. Schröder, J. Hugosson, M. J. Roobol, T. L. Tammela, S. Ciatto, V. Nelen, M. Kwiatkowski, M. Lujan, H. Lilja, M. Zappa, L. J. Denis, F. Recker, A. Berenguer, L. Määttänen, C. H. Bangma, G. Aus, A. Villers, X. Rebillard, T. van der Kwast, B. G. Blijenberg, S. M. Moss, H. J. de Koning, A. Auvinen, ERSPC Investigators, Screening and prostate-cancer mortality in a randomized European study. N. Engl. J. Med. 360, 1320-1328 (2009).
9. I. M. Thompson, D. P. Ankerst, C. Chi, P. J. Goodman, C. M. Tangen, M. S. Lucia, Z. Feng, H. L. Parnes, C. A. Coltman Jr., Assessing prostate cancer risk: Results from the Prostate Cancer Prevention Trial. J. Natl. Cancer Inst. 98, 529-534 (2006).
10. H. G. Welch, W. C. Black, Overdiagnosis in cancer. J. Natl. Cancer Inst. 102, 605-613 (2010).
11. D. Telesca, R. Etzioni, R. Gulati, Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends. Biometrics 64, 10-19 (2008).
12. G. L. Andriole, E. D. Crawford, R. L. Grubb 3rd, S. S. Buys, D. Chia, T. R. Church, M. N. Fouad, E. P. Gelmann, P. A. Kvale, D. J. Reding, J. L. Weissfeld, L. A. Yokochi, B. O'Brien, J. D. Clapp, J. M. Rathmell, T. L. Riley, R. B. Hayes, B. S. Kramer, G. Izmirlian, A. B. Miller, P. F. Pinsky, P. C. Prorok, J. K. Gohagan, C. D. Berg, PLCO Project Team, Mortality results from a randomized prostate-cancer screening trial. N. Engl. J. Med. 360, 1310-1319 (2009).
13. P. J. van Leeuwen, D. Connolly, A. Gavin, M. J. Roobol, A. Black, C. H. Bangma, F. H. Schröder, Prostate cancer mortality in screen and clinically detected prostate cancer: Estimating the screening benefit. Eur. J. Cancer 46, 377-383 (2010).
14. S. L. Chang, L. C. Harshman, J. C. Presti Jr., Impact of common medications on serum total prostate-specific antigen levels: Analysis of the National Health and Nutrition Examination survey. J. Clin. Oncol. 28, 3951-3957 (2010).
15. A. J. Vickers, A. M. Cronin, M. J. Roobol, C. J. Savage, M. Peltola, K. Pettersson, P. T. Scardino, F. H. Schröder, H. Lilja, A four-kallikrein panel predicts prostate cancer in men with recent screening: Data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam. Clin. Cancer Res. 16, 3232-3239 (2010).
16. A. Bansal, D. K. Murray, J. T. Wu, R. A. Stephenson, R. G. Middleton, A. W. Meikle, Heritability of prostate-specific antigen and relationship with zonal prostate volumes in aging twins. J. Clin. Endocrinol. Metab. 85, 1272-1276 (2000).
17. R. A. Eeles, Z. Kote-Jarai, G. G. Giles, A. A. Olama, M. Guy, S. K. Jugurnauth, S. Mulholland, D. A. Leongamornlert, S. M. Edwards, J. Morrison, H. I. Field, M. C. Southey, G. Severi, J. L. Donovan, F. C. Hamdy, D. P. Dearnaley, K. R. Muir, C. Smith, M. Bagnato, A. T. Ardern-Jones, A. L. Hall, L. T. O'Brien, B. N. Gehr-Swain, R. A. Wilkinson, A. Cox, S. Lewis, P. M. Brown, S. G. Jhavar, M. Tymrakiewicz, A. Lophatananon, S. L. Bryant, A. Horwich, R. A. Huddart, V. S. Khoo, C. C. Parker, C. J. Woodhouse, A. Thompson, T. Christmas, C. Ogden, C. Fisher, C. Jamieson, C. S. Cooper, D. R. English, J. L. Hopper, D. E. Neal, D. F. Easton, UK Genetic Prostate Cancer Study Collaborators, British Association of Urological Surgeons' Section of Oncology, UK ProtecT Study Collaborators, Multiple newly identified loci associated with prostate cancer susceptibility. Nat. Genet. 40, 316-321 (2008).
18. J. Ahn, S. I. Berndt, S. Wacholder, P. Kraft, A. S. Kibel, M. Yeager, D. Albanes, E. Giovannucci, M. J. Stampfer, J. Virtamo, M. J. Thun, H. S. Feigelson, G. Cancel-Tassin, O. Cussenot, G. Thomas, D. J. Hunter, J. F. Fraumeni Jr., R. N. Hoover, S. J. Chanock, R. B. Hayes, Variation in KLK genes, prostate-specific antigen and risk of prostate cancer. Nat. Genet. 40, 1032-1034, author reply 1035-1036 (2008).
19. F. Wiklund, S. L. Zheng, J. Sun, H. O. Adami, H. Lilja, F. C. Hsu, P. Stattin, J. Adolfsson, S. D. Cramer, D. Duggan, J. D. Carpten, B. L. Chang, W. B. Isaacs, H. Grönberg, J. Xu, Association of reported prostate cancer risk alleles with PSA levels among men without a diagnosis of prostate cancer. Prostate 69, 419-427 (2009).
20. X. Xu, C. Valtonen-André C. Sävblom, C. Halldén, H. Lilja, R. J. Klein, Polymorphisms at the Microseminoprotein-beta locus associated with physiologic variation in β-microseminoprotein and prostate-specific antigen levels. Cancer Epidemiol. Biomarkers Prev. 19, 2035-2042 (2010).
21. G. Thomas, K. B. Jacobs, M. Yeager, P. Kraft, S. Wacholder, N. Orr, K. Yu, N. Chatterjee, R. Welch, A. Hutchinson, A. Crenshaw, G. Cancel-Tassin, B. J. Staats, Z. Wang, J. Gonzalez- Bosquet, J. Fang, X. Deng, S. I. Berndt, E. E. Calle, H. S. Feigelson, M. J. Thun, C. Rodriguez, D. Albanes, J. Virtamo, S. Weinstein, F. R. Schumacher, E. Giovannucci, W. C. Willett, O. Cussenot, A. Valeri, G. L. Andriole, E. D. Crawford, M. Tucker, D. S. Gerhard, J. F. Fraumeni Jr., R. Hoover, R. B. Hayes, D. J. Hunter, S. J. Chanock, Multiple loci identified in a genome-wide association study of prostate cancer. Nat. Genet. 40, 310-315 (2008).
22. L. W. Harries, J. R. Perry, P. McCullagh, M. Crundwell, Alterations in LMTK2, MSMB and HNF1B gene expression are associated with the development of prostate cancer. BMC Cancer 10, 315 (2010).
23. L. Beke, M. Nuytten, A. Van Eynde, M. Beullens, M. Bollen, The gene encoding the prostatic tumor suppressor PSP94 is a target for repression by the Polycomb group protein EZH2. Oncogene 26, 4590-4595 (2007).
24. C. Abate-Shen, M. M. Shen, FGF signaling in prostate tumorigenesis - New insights into epithelial-stromal interactions. Cancer Cell 12, 495-497 (2007).
25. M. Rodriguez, E. Aladowicz, L. Lanfrancone, C. R. Goding, Tbx3 represses E-cadherin expression and enhances melanoma invasiveness. Cancer Res. 68, 7872-7881 (2008).
26. E. H. Blackburn, C. W. Greider, J. W. Szostak, Telomeres and telomerase: The path from maize, Tetrahymena and yeast to human cancer and aging. Nat. Med. 12, 1133-1138 (2006).
27. S. Wacholder, P. Hartge, R. Prentice, M. Garcia-Closas, H. S. Feigelson, W. R. Diver, M. J. Thun, D. G. Cox, S. E. Hankinson, P. Kraft, B. Rosner, C. D. Berg, L. A. Brinton, J. Lissowska, M. E. Sherman, R. Chlebowski, C. Kooperberg, R. D. Jackson, D. W. Buckman, P. Hui, R. Pfeiffer, K. B. Jacobs, G. D. Thomas, R. N. Hoover, M. H. Gail, S. J. Chanock, D. J. Hunter, Performance of common genetic variants in breast-cancer risk models. N. Engl. J. Med. 362, 986-993 (2010).
28. S. A. Strope, G. L. Andriole, Improving prostate-specific antigen screening. J. Clin. Oncol. 28, 2491-2492 (2010).
29. B. Holmström, M. Johansson, A. Bergh, U.-H. Stenman, G. Hallmans, P. Stattin, Prostate specific antigen for early detection of prostate cancer: Longitudinal study. BMJ 339, b3537 (2009).